UK companies in drug development relationship
Cyprotex has entered into a preclinical agreement with Avidex, the Oxford-based company that develops products for cancer and autoimmunity, with the aim of optimising a successful candidate drug that inhibits the interaction of CD80 with CD28 on T cells and blocks T cell activation.
Cyprotex has entered into a preclinical agreement with Avidex, the Oxford-based company that develops products for cancer and autoimmunity, with the aim of optimising a successful candidate drug that inhibits the interaction of CD80 with CD28 on T cells and blocks T cell activation.
Cyprotex will provide all the technologies and expertise necessary to evaluate and optimise the pre-clinical properties of Avidex's small molecule lead compounds.
'This project is recognition of the value of our integrated approach that addresses the major issues regarding the behaviour of drugs in the human body that will aid the selection of the best lead candidate,' said Dr David Leahy, chief scientific officer of Cyprotex.
According to Dr David McGibney, director of drug discovery and development at Avidex, Cyprotex was selected for this project 'because we know they can provide the essential insight that is central to the continuation of our CD80 antagonist programme'.